Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Advances in formulation and combination therapies, alongside positive clinical data, continue to fuel innovation and open new avenues for market growth
Retrieved October 25, 2017
Retatrutide for Metabolic Diseases Retatrutide shows potential benefits for individuals with: Obesity and severe obesity Insulin resistance Prediabetes and metabolic syndrome Type 2 diabetes Fatty liver associated with metabolic dysfunction Its triple-agonist profile allows simultaneous intervention across the major biological drivers of metabolic disease
US$ 24.41
US$ 28.82
US$ 24.23
US$ 22.00
US$ 27.73
US$ 20.22
US$ 28.09
US$ 24.91
US$ 27.88
